RxDoctor Payments Data

Emilee Harvey, PA

Physician Assistant · Buffalo, NYNPI 1700439015

Payments from drug & device makers

$14,348in general payments, 2019–2025

Across 750 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$780
  • Lilly USA, LLC$776
  • Pfizer$768
  • plus $4K from 28 others

What the payments were for

  • Food & beverage$14,04398%
  • Education$3042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,348 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$29,482
Medicare patients
208
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide60$57,430
XifaxanRifaximin15$52,923
Lubiprostone42$12,288
Mesalamine18$8,400
Mesalamine ErMesalamine20$8,327
MovantikNaloxegol Oxalate19$7,463
Omeprazole235$4,588
Pantoprazole Sodium295$4,573
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates63$4,122
Famotidine288$3,793
Balsalazide Disodium25$3,734
Ursodiol19$3,448
Dexlansoprazole DrDexlansoprazole16$3,340
Lansoprazole19$3,268
CholestyramineCholestyramine (With Sugar)27$2,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,723$57,43060 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,028$52,92315 claims
SandozLansoprazole$66$3,26819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →